SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-24-000140
Filing Date
2024-06-21
Accepted
2024-06-21 17:06:27
Documents
14
Period of Report
2024-06-21
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20240621.htm   iXBRL 8-K 41653
  Complete submission text file 0001725160-24-000140.txt   188893

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20240621.xsd EX-101.SCH 2158
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20240621_def.xml EX-101.DEF 4069
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20240621_lab.xml EX-101.LAB 27067
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20240621_pre.xml EX-101.PRE 16301
17 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20240621_htm.xml XML 2835
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 241061311
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)